Cart
sales@molnova.com
3-OMFP Cyclohexylammonium salt
CAS No. 21233-09-0
3-OMFP Cyclohexylammonium salt( —— )
Catalog No. M34671 CAS No. 21233-09-0
3-OMFP Cyclohexylammonium salt (OMFP Cyclohexylammonium salt) is a substrate for PTEN inhibition studies and can be used to measure enzyme activity in the catalytic structural domain of CDC25B.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 445 | Get Quote |
|
| 5MG | 686 | Get Quote |
|
| 10MG | 938 | Get Quote |
|
| 25MG | 1398 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 100MG | 2484 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Name3-OMFP Cyclohexylammonium salt
-
NoteResearch use only, not for human use.
-
Brief Description3-OMFP Cyclohexylammonium salt (OMFP Cyclohexylammonium salt) is a substrate for PTEN inhibition studies and can be used to measure enzyme activity in the catalytic structural domain of CDC25B.
-
Description3-OMFP Cyclohexylammonium salt (OMFP Cyclohexylammonium salt) is a substrate for PTEN inhibition studies and can be used to measure enzyme activity in the catalytic structural domain of CDC25B.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number21233-09-0
-
Formula Weight525.49
-
Molecular FormulaC27H28NO8P
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1OC2(C3=CC=C(OC)C=C3OC4=CC(OP(=O)(O)O)=CC=C42)C=5C=CC=CC15.NC1CCCCC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Rimantadine hydrochl...
Rimantadine Hcl (Flumadine) is an anti-influenza virus drug.
-
p-Cresyl sulfate
The p-Cresol is a protein-bound uremic retention solute. Free p-Cresol was found to be a cardiovascular risk factor in non-diabetic hemodialysis patients.
-
G108
G108 is an inhibitor of human cGAS and is used in the study of autoimmune diseases associated with human cGAS.
